macelignan and betadex

macelignan has been researched along with betadex* in 1 studies

Other Studies

1 other study(ies) available for macelignan and betadex

Article	Year
Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro. Scientific reports, 2017, 10-18, Volume: 7, Issue:1 Paclitaxel (PTX) is one of the drugs of choice in the treatment of breast and lung cancer. However, its severe side effects, including mielosuppression, cardiotoxicity and neurotoxicity, frequently cause treatment to be discontinued. Solid lipid nanoparticles (NPs) of glyceril tripalmitate (tripalmitin) loaded with PTX (Tripalm-NPs-PTX) including modifications by the addition of hexa(ethylene glycol), β-cyclodextrin and macelignan were developed. All NPs-PTX formulations displayed excellent hemocompatibility and significantly enhanced PTX antitumor activity in human breast (MCF7, MDAMB231, SKBR3 and T47D) and lung (A549, NCI-H520 and NCI-H460) cancer cells. Tripalm-NPs-PTX decreased PTX IC Topics: Antineoplastic Agents; beta-Cyclodextrins; Breast Neoplasms; Cell Line; Female; Humans; Lignans; Lung Neoplasms; MCF-7 Cells; Nanoparticles; Neoplastic Stem Cells; Paclitaxel; Polyethylene Glycols; Spheroids, Cellular; Triglycerides; Tumor Cells, Cultured	2017

Article

Year

Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro.

Scientific reports, 2017, 10-18, Volume: 7, Issue:1

Paclitaxel (PTX) is one of the drugs of choice in the treatment of breast and lung cancer. However, its severe side effects, including mielosuppression, cardiotoxicity and neurotoxicity, frequently cause treatment to be discontinued. Solid lipid nanoparticles (NPs) of glyceril tripalmitate (tripalmitin) loaded with PTX (Tripalm-NPs-PTX) including modifications by the addition of hexa(ethylene glycol), β-cyclodextrin and macelignan were developed. All NPs-PTX formulations displayed excellent hemocompatibility and significantly enhanced PTX antitumor activity in human breast (MCF7, MDAMB231, SKBR3 and T47D) and lung (A549, NCI-H520 and NCI-H460) cancer cells. Tripalm-NPs-PTX decreased PTX IC

Topics: Antineoplastic Agents; beta-Cyclodextrins; Breast Neoplasms; Cell Line; Female; Humans; Lignans; Lung Neoplasms; MCF-7 Cells; Nanoparticles; Neoplastic Stem Cells; Paclitaxel; Polyethylene Glycols; Spheroids, Cellular; Triglycerides; Tumor Cells, Cultured

2017